Theranexus (THX) Pharma has announced the appointment of Julien Veys as Deputy CEO.
Veys has served at THX since 2016 in positions including Chief Business Development Officer and Chief Operating Officer. During his time in these roles, Veys was involved in major growth stages for the company, such as the in-licensing from the Beyond Batten Disease Foundation of its Batten-1 programme in 2019 and the out-licensing of its TX01 programme to Exeltis in 2024.
Prior to this, he spent over a decade at Trophos, serving as Chief Business Development Officer as well as in other roles. While at Trophos, he played a key part in the company’s acquisition by Roche for 470m euros.
The appointment builds on THX’s planned expansion, with an ongoing strategy focusing on driving its portfolio of rare neurological disease therapies to commercialisation.
Mathieu Charvériat, chairman and CEO of THX, said: “Julien’s outstanding track record, strong expertise in strategic development and in the execution of structuring agreements, as well as his in-depth knowledge of the company and its ecosystem, are unique assets to support our transition toward a pharmaceutical company model focused on the regulatory approval and commercialisation of our drug candidates, TX01 and Batten-1.”
Veys said of his appointment: “It marks a new milestone in the history of THX, at a pivotal moment in its evolution toward the commercialisation of its medicines for rare neurological diseases. I look forward to continuing this work alongside Mathieu and the teams to implement our strategy and bring innovative therapeutic solutions to patients,”
Veys also sits on THX’s board of directors.